UPCC 11123: A Phase Ib/III Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus Placebo plus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
This Phase Ib/III study (CAPItello-292) aims to evaluate the efficacy, safety and the degree of added benefit of capivasertib combined with CDK4/6i (palbociclib, ribociclib or abemaciclib) and fulvestrant in participants with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer.
We would like to rely on WCG as the IRB of record for this study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 853855
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
